Cassava sciences reports third quarter 2023 financial and operating results

Enrollment completed for phase 3 trials evaluating oral simufilam in alzheimer's. over 1,900 patients randomized in on-going phase 3 trials.
SAVA Ratings Summary
SAVA Quant Ranking